Research & Regulatory News

Reading a Programme From Its Trial Registrations

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Coverage reported that Eli Lilly halted a bimagrumab and tirzepatide trial. The registry shows NCT06901349 as withdrawn with enrolment of zero, while three other bimagrumab trials are completed or recruiting. That is a different picture from a programme being stopped.

Key facts

NCT06901349
Phase 2, WITHDRAWN, n=0
NCT06643728
Phase 2, completed, n=252
NCT06890611
Phase 1, completed, n=125
NCT05933499
Phase 2, recruiting, n=63
Bimagrumab code
LY3985863
Withdrawn means
Never enrolled anyone
Registry checked
ClinicalTrials.gov, 21 November 2026

The distinction that changes the meaning

Registries use withdrawn and terminated for different situations. Terminated means a study started, enrolled participants and then stopped. Withdrawn means it never enrolled anyone: the record exists because the study was registered, and it closed before beginning. NCT06901349 is withdrawn with enrolment recorded as zero.

Why that matters for interpretation

A terminated trial can indicate a safety finding or a futility analysis, where something was learned from participants and acted on. A withdrawn trial with no enrolment cannot have produced any finding at all, because nobody was ever in it. Whatever the reason, it was not evidence from that study.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the rest of the programme looks like

NCT06643728 is a Phase 2 investigating weight management with bimagrumab and tirzepatide. It completed on 27 October 2026 with 252 participants (primary completion 16 January 2026). NCT06890611 is a completed Phase 1 with 125. NCT05933499 is recruiting with 63, examining body composition, insulin sensitivity and bone. Three studies at various stages alongside one that never started.

Why the bone endpoint is worth noticing

NCT05933499's registered title includes bone alongside body composition and insulin sensitivity. That reflects the point the fat-free mass literature keeps making: the compartment is not only muscle, and a trial measuring bone separately is treating it as its own question rather than folding it into a lean mass figure.

How to read a programme rather than a headline

Search the compound rather than the news. A registry search returns every registered study with its status, phase and enrolment, which describes what is actually happening more reliably than any single report about one trial. This site has already found a compound whose most-cited trial identifier pointed at an entirely different drug.

Regulatory position

Bimagrumab holds no marketing authorisation for obesity anywhere and is investigational. All the trials described are conducted under clinical supervision with ethics approval. Nothing supplied here is related to bimagrumab or to tirzepatide.

Quick reference

RegistrationPhaseStatusEnrolment
NCT069013492Withdrawn0
NCT066437282Completed252
NCT068906111Completed125
NCT059334992Recruiting63

Frequently asked questions

What is the difference between withdrawn and terminated?

Terminated means a study enrolled participants and then stopped. Withdrawn means it never enrolled anyone at all.

Was the bimagrumab programme stopped?

The registry shows one withdrawn study with zero enrolment alongside three others, two completed and one recruiting (ClinicalTrials.gov, 21 November 2026).

How should I check a programme's status?

Search the compound on ClinicalTrials.gov rather than relying on a report about one trial. Every registered study returns with its status, phase and enrolment.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.